Product Description
Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions.
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Nicholas Gulati
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Vitiligo
Phase 3: Alopecia Areata
Phase 2: Melanoma|Skin Cancer
Phase 1: Hypersensitivity, Delayed|Drug Hypersensitivity|Anal Cancer|Environmental Hypersensitivity|Oncology Unspecified|Sunburn|Skin Cancer|Transplantation Unspecified|Skin Diseases, Infectious|Carcinogenesis|Stem Cell Transplant|Erythema|Melanoma|Neurofibromatoses
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
STUDY-21-01421 | P1 |
Recruiting |
Oncology Unspecified |
2026-02-01 |
|
DERM-2016-25380 | P3 |
Completed |
Alopecia Areata |
2024-09-01 |
|
NCT05020496 | P1 |
Active, not recruiting |
Stem Cell Transplant|Transplantation Unspecified|Anal Cancer|Environmental Hypersensitivity|Erythema|Sunburn|Carcinogenesis|Skin Cancer|Skin Diseases, Infectious |
2024-06-30 |
|
STUDY-22-00650 | P1 |
Completed |
Neurofibromatoses |
2023-05-17 |